A once-daily heart failure polypill significantly improved LVEF, medication adherence, quality of life, and reduced HF hospitalizations in the POLY-HF trial published in Nature Medicine.
Written By: Mayuresh Salvi, PharmD
Reviewed By: Pharmacally Editorial Team
A new study published in Nature Medicine by researchers from the University of Texas Southwestern Medical Center reports that a once-daily polypill containing three evidence-based heart failure medications significantly improved cardiac function, enhanced treatment adherence, and reduced heart failure hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). Findings from the randomized POLY-HF trial suggest that simplifying guideline-directed medical therapy (GDMT) into a single daily capsule may overcome major barriers to optimal heart failure management while improving clinically meaningful outcomes.
Need for Simplifying Guideline-Directed Therapy
Despite major advances in pharmacological treatment, heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality worldwide. Current clinical guidelines recommend quadruple guideline-directed medical therapy (GDMT), comprising a beta-blocker, a renin-angiotensin system inhibitor or angiotensin receptor-neprilysin inhibitor (ARNI), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, and a mineralocorticoid receptor antagonist (MRA), to improve survival and reduce heart failure-related hospitalizations. However, implementing this evidence-based regimen in routine clinical practice remains challenging because patients often require multiple medications with different dosing schedules. The resulting pill burden, treatment complexity, and suboptimal medication adherence continue to limit optimal use of guideline-recommended therapy, highlighting the need for simpler treatment strategies.
POLY-HF Trial
The open-label, randomized POLY-HF trial (NCT04633005) enrolled 212 adults with symptomatic HFrEF (left ventricular ejection fraction ≤40%) across two centres in Dallas, Texas, between 2021 and 2025. The predominantly underserved study population included 54% Black participants, 33% Hispanic participants, and nearly 70% who were uninsured or dependent on county-supported healthcare.
Participants received either a once-daily polypill containing metoprolol succinate, spironolactone, and empagliflozin, while continuing a renin-angiotensin system inhibitor or sacubitril/valsartan separately, or rapid optimization of individual GDMT through enhanced usual care. The primary endpoint was change in left ventricular ejection fraction (LVEF) assessed by cardiac magnetic resonance imaging at six months.
Improved Cardiac Function and Clinical Outcomes
Among the 187 participants included in the modified intention-to-treat analysis, the polypill strategy met the primary endpoint, producing a significantly greater improvement in LVEF than enhanced usual care. Mean LVEF increased to 40.4% in the polypill group compared with 37.1% in the control group, corresponding to an adjusted between-group difference of 3.3 percentage points (95% CI, 0.2–6.4; P=0.039). Similar findings were confirmed in intention-to-treat analyses and echocardiographic assessment.
The simplified treatment strategy also translated into meaningful clinical benefits. Patients receiving the polypill experienced a 60% reduction in heart failure hospitalizations or emergency department visits (adjusted rate ratio 0.40; 95% CI, 0.18–0.88; P=0.024) and a 59% lower risk of recurrent heart failure events or death (adjusted hazard ratio 0.41; 95% CI, 0.20–0.83; P=0.013). Quality of life improved significantly, with an adjusted 8.5-point increase in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (P=0.005). A hierarchical composite analysis incorporating mortality, quality of life, heart failure events, LVEF improvement, and medication adherence also favored the polypill strategy, achieving a win ratio of 1.72 (P<0.001).
Higher Adherence with Favorable Safety
Medication adherence improved substantially with the once-daily regimen. Objective therapeutic drug monitoring demonstrated adherence in 79% of patients receiving the polypill compared with 54% in the enhanced usual care group (P=0.001). By six months, 97% of patients in the polypill arm achieved quadruple GDMT compared with 78% in the control arm, while optimal-dose GDMT was attained in 71% versus 42%, respectively.
The once-daily strategy was well tolerated, with fewer serious adverse events than enhanced usual care. One death occurred in each treatment group, and no increase was observed in clinically significant hyperkalaemia, renal dysfunction, or treatment discontinuation. Although light-headedness and genitourinary infections were reported more frequently in the polypill arm, overall tolerability remained favorable. No significant differences were observed in NT-proBNP concentrations or six-minute walk distance.
Toward Simpler Heart Failure Management
Investigators concluded that a once-daily heart failure polypill simplifies complex pharmacotherapy while improving adherence, cardiac function, quality of life, and clinical outcomes. These benefits were achieved despite comparison with an enhanced usual care strategy that actively optimized GDMT. Although larger multicentre studies with longer follow-up are needed to confirm long-term benefits and broader applicability, the POLY-HF trial provides compelling evidence that reducing medication complexity could become a practical strategy for improving implementation of guideline-directed therapy in patients with HFrEF.
What This Means for Patients
The POLY-HF findings suggest that simplifying heart failure treatment into a once-daily polypill could help patients adhere more consistently to life-saving guideline-directed therapies while reducing the burden of taking multiple medications. Although the approach requires confirmation in larger, longer-term studies before widespread adoption, it offers a promising strategy to improve treatment adherence, cardiac function, and clinical outcomes, particularly for patients who struggle with complex medication regimens.
Reference
Pandey, A., Keshvani, N., Rizvi, S.K. et al. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04504-5
About the Writer
Mayuresh Sunil Salvi (Linkedin) is a PharmD professional and healthcare writer with a strong interest in pharmacovigilance, drug safety, and emerging medical research. He is passionate about exploring new drug discoveries, clinical research, and advances in evidence-based medicine. His interests also include ward rounds, prescription audits, and treatment analysis to support rational pharmacotherapy and improved patient care.